Laws and Labels: A Regulatory View of Biosimilars
Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.
You may also like:
The latest pharmaceutical market data paint an interesting picture of the pharmacy landscape for the remainder of 2020, especially new data showing the impact of COVID-19. Industry watcher
Targeted cancer therapies, also called precision medicine or personalized medicine, involve tailoring therapy to the specific genetic variants present in a tumor. The
Filter by Type
Sign up to receive the latest news and information!